MedTrace Logo

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

NCT00839527 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 685

Last updated 2017-01-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

placebo to match albiglutide

albiglutide matching placebo weekly subcutaneous injection

BIOLOGICAL

albiglutide

albiglutide weekly subcutaneous injection

DRUG

metformin

metformin

DRUG

glimepiride

glimepiride

DRUG

pioglitazone

pioglitazone

DRUG

placebo to match pioglitazone

pioglitazone matching placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2012-01-31
Completion
2013-04-30

Countries

  • United States
  • Germany
  • Hong Kong
  • India
  • Peru
  • Philippines
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00839527 on ClinicalTrials.gov